Author/Authors :
Abdollahi، Seyed Hossein نويسنده Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran , , Ayoobi، Fateme نويسنده Physiology and Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran , , Khorramdelazad، Hossein نويسنده Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran , , Nasiri Ahmadabadi، Behzad نويسنده Immunology of Infectious Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran , , Rezayati، Mohammadtaghi نويسنده Immunology of Infectious Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran , , Arababadi، Mohammad Kazemi نويسنده Immunology of Infectious Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran , , Zare-Bidaki، Mohammad نويسنده Immunology of Infectious Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, IR Iran ,
Abstract :
Background: Zoonotic parasite Toxoplasma gondii has a high prevalence in human populations. A suitable vaccine for animals can stop the transmission of infection between animal and human.
Objectives: The aim of this study was to evaluate in vivo prepared excretory/secretory antigens (E/SA) as a potential candidate for immunization against the parasite and its effect on the production of transforming growth factor-beta (TGF-B).
Materials and Methods: Toxoplasma gondii tachyzoites were inoculated in the peritoneal cavity of mice and E/SA was harvested and used in animal immunization with and without adjuvant. Serum levels of anti-E/SA antibodies and TGF-B were measured in days 0, 3, 7, 14, 28 and 56 after immunization using ELISA technique. The measurements were statistically analyzed.
Results: Our results showed that the serum levels of anti-E/SA immunoglobulins significantly increased in all of the immunized groups. The differences of the serum levels of TGF-B between the groups were statistically significant at days 28 and 56 after immunization with E/SA.
Conclusions: Based on our study, in vivo prepared E/SA may be considered as a good candidate for animal immunization.
